CA
IDXX icon

Calton & Associates’s Idexx Laboratories IDXX Stock Holding History

Calton & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,755
Closed -$336K – 341
2018
Q1 		$336K Buy
1,755
+244
+16% +$45K 0.1% 211
2017
Q4 		$275K Buy
+1,511
New +$238K 0.07% 269

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FEF
Fundsmith Equity Fund Stamford, Connecticut $13.4B AUM
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Calton & Associates's IDXX Position: Q2 2018 in Review

Calton & Associates sold out of Idexx Laboratories (IDXX) in Q2 2018, closing a stake of 1,755 shares — an estimated $336K sold.

Calton & Associates first reported a position in IDXX in Q4 2017 and held it in 2 quarters. The position peaked at $336K in Q1 2018. 664 funds tracked by Wall St. Rank hold IDXX as of Q2 2018.

  • Calton & Associates reported no remaining Idexx Laboratories position as of Q2 2018 after selling out during the quarter.
  • Calton & Associates sold 1,755 Idexx Laboratories shares in Q2 2018, an estimated $336K.
  • Calton & Associates first reported a position in Idexx Laboratories in Q4 2017 and held it in 2 quarters.
  • Calton & Associates's Idexx Laboratories position peaked at $336K in Q1 2018.
  • 664 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2018.

Based on Calton & Associates's 13F filing for Q2 2018, filed 10 Aug 2018.